International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 2 , Pages 337-341 , 1 February 2010

Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations

  • Paul L. Nguyen, M.D.

      Affiliations

    • Harvard Radiation Oncology Program, Boston, MA
    • Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA
    • Corresponding Author InformationReprint requests to: Paul L. Nguyen, MD, Harvard Radiation Oncology Program, Department of Radiation Oncology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Tel: (616) 732-6310; Fax: (617) 732-7347
    • ,
  • Ming-Hui Chen, Ph.D.

      Affiliations

    • Department of Statistics, University of Connecticut, Storrs, CT
    • ,
  • Andrew A. Renshaw, M.D.

      Affiliations

    • Department of Pathology, Baptist Hospital of Miami, Miami, FL
    • ,
  • Marian Loffredo, R.N., O.C.N.

      Affiliations

    • Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA
    • ,
  • Philip W. Kantoff, M.D.

      Affiliations

    • Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA
    • ,
  • Anthony V. D'Amico, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA

Received 16 December 2008 ,Revised 29 January 2009 ,Accepted 29 January 2009.

References 

  1. Lin K, Lipsitz R, Miller T, et al. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:192–199
  2. Albertsen PC, Fryback DG, Storer BE, et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 1996;156:127–132
  3. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–2447
  4. Fleming ST, Rastogi A, Dmitrienko A, et al. A comprehensive prognostic index to predict survival based on multiple comorbidities: A focus on breast cancer. Med Care. 1999;37:601–614
  5. D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA. 2008;299:289–295
  6. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135
  7. Soares M, Salluh JI, Ferreira CG, et al. Impact of two different comorbidity measures on the 6-month mortality of critically ill cancer patients. Intensive Care Med. 2005;31:408–415
  8. Cox DR. Regression models and life-tables. J R Stat Soc Series B Methodol. 1972;34:187–220
  9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  10. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–2425
  11. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  12. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841–850

 Conflict of interest: none.

PII: S0360-3016(09)00186-2

doi: 10.1016/j.ijrobp.2009.01.045

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 2 , Pages 337-341 , 1 February 2010

Article Tools

* Image Usage & Resolution